Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:33 PM
Ignite Modification Date:
2025-12-24 @ 5:33 PM
NCT ID:
NCT02645968
Eligibility Criteria:
Inclusion Criteria:
* Signed informed consent
* Able to read and understand the scope and nature of data collection
* Aged ≥ 18 at time of informed consent
* Patients diagnosed with interstitial lung disease (ILD). Patients with suspicion on interstitial lung disease cannot be included into the registry, only after consens diagnosis of an ILD. This is also the case for patients with not classifiable ILDs.
Subjects with the following subtypes of ILD will be enrolled:
1. Idiopathic interstitial pneumonia (IIPs)
* Idiopathic pulmonary fibrosis (IPF)
* Non-specific interstitial pneumonia (NSIP)
* Desquamative interstitial pneumonia (DIP)
* Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD)
* Cryptogenic organizing pneumonia (COP)
* Lymphocytic interstitial pneumonia (LIP)
* Acute interstitial pneumonia (AIP)
* Rare forms of IIPs (e.g. pleuropulmonary fibroelastosis)
* Not classifiable IIP
2. Granulomatous lung disease
* Sarcoidosis
* Berylliosis
* Other (e.g. involvement in chronic inflammatory liver and gut diseases, except EAA)
3. Hypersensitivity pneumonitis (exogen allergic alveolitis (EAA))
* Farmer's lung
* Bird keepers' lung disease
* Origin unknown
* Other
4. Rheumatic and connective tissue diseases with pulmonary involvement like:
* Connective tissue disease (subtype)
* Vasculitis
* Rheumatoid arthritis
5. Pneumoconiosis
* Asbestosis
* Silicosis
* Other
6. Other forms
* Pulmonary lymphangioleiomyomatosis
* Pulmonary Langerhans' cell histiocytosis
* Pulmonary alveolar proteinosis
* Eosinophilic pneumonia
* Post-ARDS Fibrosis
7. Drug-related
8. Radiotherapy associated
9. Fibrosis in emphysema patients without signs of other ILDs (i.e. smoking related interstitial fibrosis or "emphysemasclerosis")
10. Others
11. Not classifiable
Furthermore for each subtype it will be queried, if a diagnosis of concomitant emphysema in ILD was made.
Exclusion Criteria:
\- Patients without interstitial lung disease
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02645968
Study Brief:
Protocol Section:
NCT02645968